Optimism regarding revenue growth of global pharmaceutical
manufacturers, CROs and CMOs remained stable in 2011 and decreased
marginally in 2012. However, it is projected that revenue expectations
in both emerging and recovering developed markets will sustain growth
levels in 2012. For example, Gen-Probe Incorporated, a developer and
manufacturer of molecular diagnostic products based in the US, achieved a
growth of 16%in revenues for Q42011, and expect similar growth in 2012.
Additionally, the company reported revenues of US$576.2 million in
2011, an increase of 6% from US$543.3 million in 2010, and also expects
further boost in its revenue up to US$655 million in 2012.
Following the global financial crisis in 2008–2009, and the subsequent European debt crisis in 2011, global pharmaceutical manufacturing companies have accelerated their focus to reduce the cost of drugs leading to a renewed evaluation of opportunities in the outsourcing of manufacturing activities. These incidents favor the growth of the pharmaceutical market in emerging economies and also present opportunities for CROs and CMOs. Moreover, manufacturing companies that intend to expand in these markets will increasingly rely on existing CMOs before setting up indigenous plants. This strategy helps pharmaceutical manufacturing companies to test the potential of such markets without undertaking too many risks themselves, and also reduce their transportation costs to a considerable extent, increasing the level of optimism about revenue growth among CROs and CMOs.
Business Indicators in the Pharmaceutical Industry - 2012-2013
Published: June 2012 No. of Pages: 66
Price: Single User: US $ 700 Corporate User: US $ 2100
Although optimism levels across all segments of respondent have dipped marginally for 2012 as compared with 2011, suppliers are deemed to be ‘more optimistic’ than other segments of the global pharmaceutical industry. On average, 52% of global pharmaceutical industry supplier respondents are ‘more optimistic’ about revenue growth, as compared with 44% and 43% of respective respondents from pharmaceutical manufacturers, and CROs and CMOs. The existing growth optimism for supplier companies is factored by the increase in the number of prescriptions with generic drugs and drastic expansion plans of key pharmaceutical companies in emerging markets.
About ICD Research
ICD Research is a full-service global market research agency and premium business information brand specializing in industry analysis in a wide set of B2B and B2C markets. ICD Research has access to over 400 in-house analysts and journalists and a global media presence in over 30 professional markets enabling us to conduct unique and insightful research via our trusted business communities. Through its unique B2B and B2C research panels and access to key industry bodies, ICD Research delivers insightful and actionable analysis. The ICD Research survey capabilities grant readers access to the opinions and strategies of key business decision makers, industry experts and competitors as well as examining their actions surrounding business priorities.
About Strategic Defence Intelligence
Strategic Defence Intelligence's unique monitoring platform tracks global defence activity for over 2,500 companies and 65 product categories in real time and in a highly structured manner, giving a comprehensive and easily-searchable picture of all defence industry activity. The site features: daily updated analysis, comment and news, company and customer profiles, defence spending, tenders and contracts, product and technology intelligence, a research and analysis database providing access to industry and competitor reports to enable business and market planning, and fully customizable tools, including instant personalized report generation and custom alerts.
Following the global financial crisis in 2008–2009, and the subsequent European debt crisis in 2011, global pharmaceutical manufacturing companies have accelerated their focus to reduce the cost of drugs leading to a renewed evaluation of opportunities in the outsourcing of manufacturing activities. These incidents favor the growth of the pharmaceutical market in emerging economies and also present opportunities for CROs and CMOs. Moreover, manufacturing companies that intend to expand in these markets will increasingly rely on existing CMOs before setting up indigenous plants. This strategy helps pharmaceutical manufacturing companies to test the potential of such markets without undertaking too many risks themselves, and also reduce their transportation costs to a considerable extent, increasing the level of optimism about revenue growth among CROs and CMOs.
Business Indicators in the Pharmaceutical Industry - 2012-2013
Published: June 2012 No. of Pages: 66
Price: Single User: US $ 700 Corporate User: US $ 2100
Although optimism levels across all segments of respondent have dipped marginally for 2012 as compared with 2011, suppliers are deemed to be ‘more optimistic’ than other segments of the global pharmaceutical industry. On average, 52% of global pharmaceutical industry supplier respondents are ‘more optimistic’ about revenue growth, as compared with 44% and 43% of respective respondents from pharmaceutical manufacturers, and CROs and CMOs. The existing growth optimism for supplier companies is factored by the increase in the number of prescriptions with generic drugs and drastic expansion plans of key pharmaceutical companies in emerging markets.
About ICD Research
ICD Research is a full-service global market research agency and premium business information brand specializing in industry analysis in a wide set of B2B and B2C markets. ICD Research has access to over 400 in-house analysts and journalists and a global media presence in over 30 professional markets enabling us to conduct unique and insightful research via our trusted business communities. Through its unique B2B and B2C research panels and access to key industry bodies, ICD Research delivers insightful and actionable analysis. The ICD Research survey capabilities grant readers access to the opinions and strategies of key business decision makers, industry experts and competitors as well as examining their actions surrounding business priorities.
About Strategic Defence Intelligence
Strategic Defence Intelligence's unique monitoring platform tracks global defence activity for over 2,500 companies and 65 product categories in real time and in a highly structured manner, giving a comprehensive and easily-searchable picture of all defence industry activity. The site features: daily updated analysis, comment and news, company and customer profiles, defence spending, tenders and contracts, product and technology intelligence, a research and analysis database providing access to industry and competitor reports to enable business and market planning, and fully customizable tools, including instant personalized report generation and custom alerts.
No comments:
Post a Comment